• Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $415 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-168 Mln

Adc Therapeutics SA (ADCT) Share Price

$4.86

As on 28-Feb-2024 16:10 EST

up-down-arrow $-0.15-2.99%

  • Prev Close info

    $5.01

  • Day's Openinfo

    $5.05

  • Today's Highinfo

    $5.14

  • Today's Lowinfo

    $4.81

  • Today's Volumeinfo

    347,967

  • 52 Week rangeinfo

    $0.36 - 6.04

Please wait...

Adc Therapeutics SA (ADCT) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Adc Therapeutics SA (ADCT)
192.77 82.02 571.73 19.41 -43.25 -- --
S&P BSE Sensex
0.09 2.27 9.60 21.95 13.77 15.03 13.17
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 28-Feb-2024  |  #As on 26-Oct-2023
2023
2022
2021
Adc Therapeutics SA (ADCT)
-56.77 -80.99 -36.89
S&P Small-Cap 600
13.89 -17.42 25.27
S&P BSE Sensex
18.74 4.44 21.99

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Adc Therapeutics SA (ADCT) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Adc Therapeutics SA (ADCT)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Adc Therapeutics SA (ADCT)

        CEO & Director

        Dr. Ameet Mallik M.B.A., M.S.

        Chief Financial Officer

        Mr. Jose I. Carmona M.B.A.

        Headquarters

        Epalinges

        FAQs for Adc Therapeutics SA (ADCT)

        The total asset value of Adc Therapeutics SA (ADCT) stood at $ 545 Mln as on 30-Sep-23

        The share price of Adc Therapeutics SA (ADCT) is $4.86 (NYSE) as of 28-Feb-2024 16:10 EST. Adc Therapeutics SA (ADCT) has given a return of -43.25% in the last 3 years.

        Adc Therapeutics SA (ADCT) has a market capitalisation of $ 415 Mln as on 28-Feb-2024. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Adc Therapeutics SA (ADCT) is 2.58 times as on 28-Feb-2024, a -0.13% premium to its peers’ median range of 2.98 times.

        Since, TTM earnings of Adc Therapeutics SA (ADCT) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Adc Therapeutics SA (ADCT) and enter the required number of quantities and click on buy to purchase the shares of Adc Therapeutics SA (ADCT).

        ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; and LOTIS-7, a Phase Ib clinical trial for treatment of relapsed or refractory B-cell lineage non-hodgkin lymphoma (B-NHL). The company is also developing camidanlumab tesirine, an ADC composed of a monoclonal antibody that binds to CD25 conjugated to a PBD"dimer toxin, as well as in Phase II clinical trial in relapsed or refractory hodgkin lymphoma. In addition, it develops ADCT-602, which is in Phase I/II clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 that are in Phase Ia clinical trial for treatment of various solid tumors and hematological malignancies; and ADCT-212, a second-generation PBD-based ADC targeting prostate-specific membrane antigen (PSMA), including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland. Address: Biopole, Epalinges, Switzerland, 1066

        The CEO & director of Dr. Ameet Mallik M.B.A., M.S.. is Adc Therapeutics SA (ADCT), and CFO & Sr. VP is Mr. Jose I. Carmona M.B.A..

        The promoters of Adc Therapeutics SA (ADCT) have pledged 0% of the total equity as on Sep-23.

        Adc Therapeutics SA (ADCT) Ratios
        Return on equity(%)
        --
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        --
        Dividend yield(%)
        --

        No, TTM profit after tax of Adc Therapeutics SA (ADCT) was $-168 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $414.50 Mln
        • Revenue (TTM)revenue-information $122.57 Mln
        • Earnings (TTM) earning-information $-167.58 Mln
        • Cash date-information $310.41 Mln
        • Total Debt info $123.53 Mln
        • Insider's Holding 35.28%
        • Liquidity liquidity High
        • 52 Week range week-range $0.36 - 6.04
        • Shares outstanding share-outstanding 80,642,496
        • 7 Years Aggregate:

          CFO: $-958.29 Mln

          EBITDA: $-901.69 Mln

          Net Profit: $-1,140.07 Mln

        About The Company

        • IPO Date 16-Mar-1979
        • CEO & Director Dr. Ameet Mallik M.B.A., M.S.
        • Chief Financial Officer Mr. Jose I. Carmona M.B.A.
        • Listing key-listing NYSE: ADCT
        • Country Switzerland
        • Headquarters headquarters Epalinges
        • Website website https://www.adctherapeutics.com
        • Business

          ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the...  treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; and LOTIS-7, a Phase Ib clinical trial for treatment of relapsed or refractory B-cell lineage non-hodgkin lymphoma (B-NHL). The company is also developing camidanlumab tesirine, an ADC composed of a monoclonal antibody that binds to CD25 conjugated to a PBD"dimer toxin, as well as in Phase II clinical trial in relapsed or refractory hodgkin lymphoma. In addition, it develops ADCT-602, which is in Phase I/II clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 that are in Phase Ia clinical trial for treatment of various solid tumors and hematological malignancies; and ADCT-212, a second-generation PBD-based ADC targeting prostate-specific membrane antigen (PSMA), including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland. Address: Biopole, Epalinges, Switzerland, 1066  Read more

        share-fund-plan-icon